Evaluation of Tolerability of O3R-5671-PRO in Single and Multiple Doses in Healthy Adults with Inflammatory Bowel Diseases and Psoriasis

The primary objective of this study is to evaluate the **tolerability** of single and multiple doses of O3R-5671-PRO in healthy adult subjects. This is clinically relevant as it provides foundational safety data necessary for further development of the treatment for conditions such as **inflammatory bowel diseases** and **psoriasis**. Understanding the tolerability in a healthy population is a critical step before advancing to patient populations.

The clinical trial involves **male** participants diagnosed with **inflammatory bowel diseases** and **psoriasis**. The study population is composed of adults aged 18 to 64 years. Participants were selected based on specific criteria, although the sponsor has not provided detailed information regarding the total number of participants or the principal inclusion criteria. The trial does not include a vulnerable population, and no specific lifestyle considerations such as diet or physical activity have been highlighted. The sponsor has not disclosed further details about the general health status or habits of the participants.

The clinical trial is designed to evaluate the **tolerability** of single and multiple doses of O3R-5671-PRO in healthy adult subjects. This study is a Phase 1 trial, which is typically the first stage of testing in human subjects and focuses on assessing safety and dosage. The trial is structured as a randomized, double-blind, and controlled study to ensure the reliability and validity of the results. The estimated recruitment start date is August 18, 2025, with an anticipated end date of February 5, 2026, indicating a total trial duration of approximately six months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This initial visit will involve a comprehensive assessment to ensure that participants meet the necessary health standards for inclusion in the trial. Following successful screening, participants will be randomly assigned to receive either the investigational product or a placebo, with neither the participants nor the investigators aware of the group assignments, maintaining the double-blind nature of the study.

Throughout the trial, participants will attend regular follow-up visits to monitor their health and assess the effects of the treatment. These visits will include physical examinations, laboratory tests, and other relevant assessments to gather data on the safety and tolerability of the investigational product. The end-of-study visit will mark the conclusion of the participant's involvement, during which final evaluations will be conducted to ensure participant safety and collect any remaining data.

The expected length of participant involvement is contingent upon the trial's schedule and individual response to the treatment. Conditions that may lead to early termination from the study include adverse reactions, non-compliance with study procedures, or withdrawal of consent by the participant. The trial's design and procedures are meticulously planned to ensure the collection of high-quality data while prioritizing participant safety and well-being.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the study may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the source data, further details about the **experimental medication** and any **non-experimental treatments** cannot be provided. The trial documentation should be consulted for comprehensive information regarding the treatments used in this clinical trial.

The clinical trial is designed to assess the efficacy of an investigational product. The trial is categorized as a Phase 1 study, which typically focuses on evaluating the safety, tolerability, and pharmacokinetics of the product in a small group of participants. Although specific efficacy endpoints are not detailed, Phase 1 trials may include preliminary assessments of efficacy through various parameters such as biomarker levels or symptom improvement scores. These assessments are generally conducted using validated scales or laboratory tests at predetermined timepoints throughout the trial duration. The estimated recruitment start date is August 18, 2025, with an anticipated end date of February 5, 2026. The trial will adhere to rigorous data collection and analysis protocols to ensure the reliability and validity of the efficacy outcomes.